Home / Health / "Miracle" AIDS Drug Launched in Eswatini
"Miracle" AIDS Drug Launched in Eswatini
24 Mar
Summary
- A new twice-yearly injection drug, Lenacapavir, offers near complete protection.
- The drug is being introduced in nine high-risk countries, starting with Eswatini.
- Recent foreign aid cuts have severely disrupted HIV response efforts globally.
A groundbreaking twice-yearly injection, Lenacapavir, is offering renewed hope in the global fight against AIDS. Described as the closest advancement to a vaccine, it provides near complete protection against HIV infection.
This innovative treatment is now being introduced in Eswatini, a nation with historically high HIV rates, marking the first distribution in one of nine at-risk countries. This rollout is particularly crucial as recent substantial cuts to foreign aid by the US, UK, and European nations have critically disrupted HIV response efforts worldwide, impacting testing, treatment, and prevention.
Lenacapavir, developed by Gilead Sciences, is being made available at a significantly reduced cost in lower-income countries. This initiative aims to prevent millions of new infections and potentially end the AIDS epidemic by 2030. The UN's goal is to deliver the treatment to two million people by 2028.
However, concerns remain about the limited scope of the current rollout, with experts warning that global investment is essential for full impact. The UN UNAIDS has set a target of 20 million people on PrEP in the coming years, significantly exceeding the current Lenacapavir distribution plan. The cost of not addressing the epidemic at scale is projected to be immense, with millions more infections and deaths anticipated if funding and access are not prioritized.
